261 related articles for article (PubMed ID: 15579507)
1. The major podocyte protein nephrin is transcriptionally activated by the Wilms' tumor suppressor WT1.
Wagner N; Wagner KD; Xing Y; Scholz H; Schedl A
J Am Soc Nephrol; 2004 Dec; 15(12):3044-51. PubMed ID: 15579507
[TBL] [Abstract][Full Text] [Related]
2. WT1 activates a glomerular-specific enhancer identified from the human nephrin gene.
Guo G; Morrison DJ; Licht JD; Quaggin SE
J Am Soc Nephrol; 2004 Nov; 15(11):2851-6. PubMed ID: 15504938
[TBL] [Abstract][Full Text] [Related]
3. Murine Denys-Drash syndrome: evidence of podocyte de-differentiation and systemic mediation of glomerulosclerosis.
Patek CE; Fleming S; Miles CG; Bellamy CO; Ladomery M; Spraggon L; Mullins J; Hastie ND; Hooper ML
Hum Mol Genet; 2003 Sep; 12(18):2379-94. PubMed ID: 12915483
[TBL] [Abstract][Full Text] [Related]
4. Transcriptional activation of the syndecan-1 promoter by the Wilms' tumor protein WT1.
Cook DM; Hinkes MT; Bernfield M; Rauscher FJ
Oncogene; 1996 Oct; 13(8):1789-99. PubMed ID: 8895526
[TBL] [Abstract][Full Text] [Related]
5. WT1 induces apoptosis through transcriptional regulation of the proapoptotic Bcl-2 family member Bak.
Morrison DJ; English MA; Licht JD
Cancer Res; 2005 Sep; 65(18):8174-82. PubMed ID: 16166292
[TBL] [Abstract][Full Text] [Related]
6. Wnt-4 regulation by the Wilms' tumour suppressor gene, WT1.
Sim EU; Smith A; Szilagi E; Rae F; Ioannou P; Lindsay MH; Little MH
Oncogene; 2002 May; 21(19):2948-60. PubMed ID: 12082525
[TBL] [Abstract][Full Text] [Related]
7. Anlaysis of complementary expression profiles following WT1 induction versus repression reveals the cholesterol/fatty acid synthetic pathways as a possible major target of WT1.
Rae FK; Martinez G; Gillinder KR; Smith A; Shooter G; Forrest AR; Grimmond SM; Little MH
Oncogene; 2004 Apr; 23(17):3067-79. PubMed ID: 15021918
[TBL] [Abstract][Full Text] [Related]
8. The Wilms' tumor suppressor Wt1 activates transcription of the erythropoietin receptor in hematopoietic progenitor cells.
Kirschner KM; Hagen P; Hussels CS; Ballmaier M; Scholz H; Dame C
FASEB J; 2008 Aug; 22(8):2690-701. PubMed ID: 18424770
[TBL] [Abstract][Full Text] [Related]
9. The zinc finger domain of Wilms' tumor 1 suppressor gene (WT1) behaves as a dominant negative, leading to abrogation of WT1 oncogenic potential in breast cancer cells.
Han Y; San-Marina S; Yang L; Khoury H; Minden MD
Breast Cancer Res; 2007; 9(4):R43. PubMed ID: 17634147
[TBL] [Abstract][Full Text] [Related]
10. Analysis of WT1 target gene expression in stably transfected cell lines.
Thäte C; Englert C; Gessler M
Oncogene; 1998 Sep; 17(10):1287-94. PubMed ID: 9771972
[TBL] [Abstract][Full Text] [Related]
11. Intrauterine growth restriction leads to a dysregulation of Wilms' tumour supressor gene 1 (WT1) and to early podocyte alterations.
Menendez-Castro C; Hilgers KF; Amann K; Daniel C; Cordasic N; Wachtveitl R; Fahlbusch F; Plank C; Dötsch J; Rascher W; Hartner A
Nephrol Dial Transplant; 2013 Jun; 28(6):1407-17. PubMed ID: 23229934
[TBL] [Abstract][Full Text] [Related]
12. Functional characterization of WT1 binding sites within the human vitamin D receptor gene promoter.
Lee TH; Pelletier J
Physiol Genomics; 2001 Dec; 7(2):187-200. PubMed ID: 11773605
[TBL] [Abstract][Full Text] [Related]
13. The Wilms' tumor gene Wt1 is required for normal development of the retina.
Wagner KD; Wagner N; Vidal VP; Schley G; Wilhelm D; Schedl A; Englert C; Scholz H
EMBO J; 2002 Mar; 21(6):1398-405. PubMed ID: 11889045
[TBL] [Abstract][Full Text] [Related]
14. Ligand-activated Ahr signaling leads to disruption of nephrogenesis and altered Wilms' tumor suppressor mRNA splicing.
Falahatpisheh MH; Ramos KS
Oncogene; 2003 Apr; 22(14):2160-71. PubMed ID: 12687018
[TBL] [Abstract][Full Text] [Related]
15. A splice variant of the Wilms' tumour suppressor Wt1 is required for normal development of the olfactory system.
Wagner N; Wagner KD; Hammes A; Kirschner KM; Vidal VP; Schedl A; Scholz H
Development; 2005 Mar; 132(6):1327-36. PubMed ID: 15716344
[TBL] [Abstract][Full Text] [Related]
16. Expression of the Wilms' tumor suppressor gene, WT1, reduces the tumorigenicity of the leukemic cell line M1 in C.B-17 scid/scid mice.
Smith SI; Down M; Boyd AW; Li CL
Cancer Res; 2000 Feb; 60(4):808-14. PubMed ID: 10706085
[TBL] [Abstract][Full Text] [Related]
17. Transcriptional regulation by the Wilms' tumour suppressor protein WT1.
Wagner KJ; Roberts SG
Biochem Soc Trans; 2004 Dec; 32(Pt 6):932-5. PubMed ID: 15506928
[TBL] [Abstract][Full Text] [Related]
18. Nephrin-signature molecule of the glomerular podocyte?
Welsh GI; Saleem MA
J Pathol; 2010 Feb; 220(3):328-37. PubMed ID: 19950250
[TBL] [Abstract][Full Text] [Related]
19. Isoforms of Wilms' tumor suppressor gene (WT1) have distinct effects on mammary epithelial cells.
Burwell EA; McCarty GP; Simpson LA; Thompson KA; Loeb DM
Oncogene; 2007 May; 26(23):3423-30. PubMed ID: 17160023
[TBL] [Abstract][Full Text] [Related]
20. Transcriptional regulation of podocyte specification and differentiation.
Quaggin SE
Microsc Res Tech; 2002 May; 57(4):208-11. PubMed ID: 12012385
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]